{
    "clinical_study": {
        "@rank": "58894", 
        "arm_group": [
            {
                "arm_group_label": "KALOMIN\u2122 Tab.", 
                "arm_group_type": "Experimental", 
                "description": "KALOMIN\u2122 Tab./Placebo to Umckamin syrup"
            }, 
            {
                "arm_group_label": "Umckamin syrup", 
                "arm_group_type": "Active Comparator", 
                "description": "Umckamin syrup/Placebo to KALOMIN\u2122 Tab."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, double-dummy, double-blind, randomized, active-controlled, parallel\n      group phase 3 clinical trial to evaluate the efficacy and safety of KALOMIN\u2122 Tab. in\n      patients with acute bronchitis.\n\n      The aim of this clinical trial is to demonstrate that KALOMIN\u2122 Tab. is clinically\n      non-inferior to Umckamin syrup, as assessed by BSS(Bronchitis Severity Score), in the\n      treatment of acute bronchitis after 7 days."
        }, 
        "brief_title": "Safety and Efficacy of KALOMIN\u2122 Tab. in Patients With Acute Bronchitis", 
        "condition": "Acute Bronchitis", 
        "condition_browse": {
            "mesh_term": [
                "Bronchitis", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients aged 12-75 years old\n\n          -  A total score of BSS \u2265 5\n\n          -  The duration of symptoms had to be less than 14 days and no chronic pulmonary disease\n\n          -  Patients who voluntarily sign a written informed consent to participate in the trial\n\n        Exclusion Criteria:\n\n          -  Indication for antibiotic treatment(e.g. severe respiratory infection)\n\n          -  Allergic bronchial asthma\n\n          -  Tendency to bleed\n\n          -  Severe heart, renal, or liver diseases or decline of immune function\n\n          -  Chronic obstructive pulmonary disease\n\n          -  Known or supposed hypersensitivity to investigational medication\n\n          -  Treatment with antibiotics during the past 4 weeks prior to inclusion in the trial\n\n          -  Women during pregnancy or lactation period\n\n          -  Clinically significant abnormal values in the screening test(more than twice the\n             upper limit of normal range for ALT, AST, BUN, and Serum Creatinine)\n\n          -  Participation in any other trial within 30 days prior to inclusion in the trial\n\n          -  Unsuitable patients for enrollment in the opinion of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "242", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151734", 
            "org_study_id": "KUP-KLM_301"
        }, 
        "intervention": [
            {
                "arm_group_label": "KALOMIN\u2122 Tab.", 
                "intervention_name": "KALOMIN\u2122 Tab.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Umckamin syrup", 
                "intervention_name": "Umckamin syrup", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Total score of BSS(Bronchitis Severity Score)", 
            "safety_issue": "No", 
            "time_frame": "7days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151734"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Individual symptom score of BSS", 
                "safety_issue": "No", 
                "time_frame": "7days"
            }, 
            {
                "measure": "reaction rate of treatment", 
                "safety_issue": "No", 
                "time_frame": "7days"
            }, 
            {
                "measure": "IMOS(Integrative Medicine Outcome Scale)", 
                "safety_issue": "No", 
                "time_frame": "7days"
            }, 
            {
                "measure": "IMPSS(Integrative Medicine Patient Satisfaction Scale)", 
                "safety_issue": "No", 
                "time_frame": "7days"
            }, 
            {
                "measure": "Adverse events, clinical laboratory examination, physical examination, etc.", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }
        ], 
        "source": "Korea United Pharm. Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea United Pharm. Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}